The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment.
Nawal MerjanehMona HajjarYing-Wei LanVladimir V KalinichenkoTanya V KalinPublished in: Cancers (2024)
Forkhead box M1 (FOXM1) is a transcription factor in the forkhead (FOX) family, which is required for cellular proliferation in normal and neoplastic cells. FOXM1 is highly expressed in many different cancers, and its expression is associated with a higher tumor stage and worse patient-related outcomes. Abnormally high expression of FOXM1 in cancers compared to normal tissue makes FOXM1 an attractive target for pharmacological inhibition. FOXM1-inhibiting agents and specific FOXM1-targeted small-molecule inhibitors have been developed in the lab and some of them have shown promising efficacy and safety profiles in mouse models. While the future goal is to translate FOXM1 inhibitors to clinical trials, potential synergistic drug combinations can maximize anti-tumor efficacy while minimizing off-target side effects. Hence, we discuss the rationale and efficacy of all previously studied drug combinations with FOXM1 inhibitors for cancer therapies.
Keyphrases
- transcription factor
- small molecule
- clinical trial
- poor prognosis
- signaling pathway
- induced apoptosis
- squamous cell carcinoma
- emergency department
- binding protein
- type diabetes
- case report
- randomized controlled trial
- metabolic syndrome
- mouse model
- machine learning
- dna binding
- endoplasmic reticulum stress
- phase ii
- skeletal muscle
- young adults
- big data
- lymph node metastasis